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Introduction. For many years, coronary heart disease (CHD) has been the 
leading cause of mortality in the world. Coronary atherosclerosis (AS) is the 
morphological basis of CHD. In the formation of atherosclerotic plaque, the 
leading role of numerous inflammatory mediators and reactions involving 
immunocompetent cells has been proven [1]. 
Today, myocardial changes in CHD are represented as an ischemic-
reperfusion injury, which is a complex process involving the interaction of a 
number of cells, including endothelium and immunocompetent cells, as well as 
the coagulation system components. The activation of chronic systemic 
inflammation (CSI) underlies endothelial dysfunction, vasoconstriction, platelet 
activation, and myocardial microcirculation impairment. Proinflammatory 
cytokines (CK) promote the expression of pain mediators, activate the vagus 
afferent receptors, and cause a negative inotropic effect [2]. 
The molecular mechanisms of atherogenesis and myocardial impairment 
in CHD are studied in detail in order to find new targets for pharmacological 
effect. According to modern scientific research, polyphenolic compounds of 
natural origin possess numerous mechanisms of anti-inflammatory activity, 
implemented at different levels of cellular organization [3, 4]. 
The aim of our research was to study the indicators of chronic systemic 
inflammation in patients with stable coronary heart disease, their relationship 
with the parameters of myocardial ischemia and the effect of quercetin on the 
detected disorders. 
Materials and methods. The study included 85 patients of both sexes, 
aged from 48 to 67, with the diagnosis of coronary heart disease: stable 
exertional angina, FC II, HF 0-I. Patients were divided by random sampling into 
2 groups – the study group (30 patients) and the comparison group (55 patients). 
Patients were examined to determine the level of tumor necrosis factor alpha 
(TNFα) and interleukin-1β (ІL-1β) in the serum by immunoenzymatic assay, the 
content of fibrinogen (FG) in the blood plasma by weight and 24-hour ECG 
Holter monitoring (HM) was performed with the calculation of total myocardial 
ischemia – the total duration of episodes of ST segment depression (Σt ST depr) 
and the total number of episodes of ST depr in three registration leads [5, 6]. All 
patients received standard therapy (β-blockers, statins, aspirin), patients in the 
study group were additionally prescribed quercetin at a dose of 120 mg per day. 
In 2 months, patients were re-examined to the aforementioned extent of studies. 
Results. All patients with coronary heart disease had an elevated blood 
level of TNFα (8.68+2.44 pg / ml) and IL-1β (9.58+3.24 pg / ml), FG content in 
the blood plasma was elevated in 37% of patients. The daily Σt ST depr was 
52.92+13.00 min. The number of episodes of ST depr was 10.58+2.83. We 
found a direct correlation relationship of moderate strength between the level of 
TNFα and Σt ST depr (r=0.3363, p<0.01), TNFα level and the number of 
episodes of ST depr (r=0.413, p<0.01), the content of FG and Σt ST depr 
(r=0.408, p<0.01), and the content of FG and the number of episodes of ST depr 
(r=0.410, p<0.001). These findings demonstrate the correlation between chronic 
systemic inflammation and myocardial ischemia. After two months of treatment 
in the comparison group, there were no reliable changes in the levels of 
proinflammatory cytokines. The exposure to quercetin significantly decreased 
the level of IL-1β (by 17.4%, p=0.002) and TNFα (by 23%, p=0.048). In both 
groups, the level of fibrinogen was reliably decreased, but more significantly 
under the influence of quercetin (p=0.0004). According to the data of ECG HM, 
in the study group, the number of episodes of ST depr decreased by 27.6%, 
whereas in the comparison group – by 15.9%. In patients of the comparison 
group, Σt ST depr decreased by 20.7%, in patients who additionally received 
quercetin – by 34.9% (up to 32.7+13.08 min.), and the value was significantly 
different from that of the comparison group (p<0.05). 
Conclusion. In patients with CHD, the increased level of chronic 
systemic inflammation correlates with the severity of myocardial ischemia. The 
use of quercetin in the comprehensive therapy of patients with CHD had an anti-
inflammatory effect, and contributed to a decrease in the number and duration of 
episodes of myocardial ischemia, which may be due to its anti-inflammatory 
properties. 
Prospects for further research. The obtained results substantiate the 
expediency of using the inflammatory markers for assessing the course and 
progression of CHD. The detected efficacy of quercetin in the correction of CSI 
level and myocardial ischemia forms the basis for further research to include it 
in the integrated therapy of CHD. 
The results of the study demonstrate the need for further in-depth study of 
the molecular mechanisms of CHD pathogenesis for the development of new 
therapeutic strategies to improve patients’ quality of life. 
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